vs
AIR LEASE CORP（AL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是AIR LEASE CORP的1.5倍（$207.3M vs $140.8M），AIR LEASE CORP净利率更高（128.5% vs -62.0%，领先190.5%），AIR LEASE CORP同比增速更快（90.4% vs 25.9%），AIR LEASE CORP自由现金流更多（$342.1M vs $-100.8M），过去两年AIR LEASE CORP的营收复合增速更高（69.6% vs 38.0%）
航空租赁公司（ALC）是2010年成立的美国飞机租赁企业，由史蒂文·F·乌德瓦-哈齐执掌运营。公司直接向波音、空客、巴航工业、ATR采购全新商用飞机，为全球各地航空公司客户提供专业的飞机租赁及融资服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AL vs RARE — 直观对比
营收规模更大
RARE
是对方的1.5倍
$140.8M
营收增速更快
AL
高出64.5%
25.9%
净利率更高
AL
高出190.5%
-62.0%
自由现金流更多
AL
多$442.9M
$-100.8M
两年增速更快
AL
近两年复合增速
38.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.8M | $207.3M |
| 净利润 | $180.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 128.5% | -62.0% |
| 营收同比 | 90.4% | 25.9% |
| 净利润同比 | 60.2% | 3.5% |
| 每股收益（稀释后） | $1.49 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALRARE
| Q4 25 | $140.8M | $207.3M | ||
| Q3 25 | $44.5M | $159.9M | ||
| Q2 25 | $53.0M | $166.5M | ||
| Q1 25 | $92.9M | $139.3M | ||
| Q4 24 | $74.0M | $164.6M | ||
| Q3 24 | $65.0M | $139.5M | ||
| Q2 24 | $57.8M | $147.0M | ||
| Q1 24 | $49.0M | $108.8M |
净利润ALRARE
| Q4 25 | $180.9M | $-128.6M | ||
| Q3 25 | $146.5M | $-180.4M | ||
| Q2 25 | $385.2M | $-115.0M | ||
| Q1 25 | $375.8M | $-151.1M | ||
| Q4 24 | $112.9M | $-133.2M | ||
| Q3 24 | $104.0M | $-133.5M | ||
| Q2 24 | $102.9M | $-131.6M | ||
| Q1 24 | $107.9M | $-170.7M |
营业利润率ALRARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | — | -106.9% | ||
| Q2 25 | — | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率ALRARE
| Q4 25 | 128.5% | -62.0% | ||
| Q3 25 | 329.2% | -112.8% | ||
| Q2 25 | 726.9% | -69.0% | ||
| Q1 25 | 404.5% | -108.5% | ||
| Q4 24 | 152.7% | -80.9% | ||
| Q3 24 | 160.0% | -95.7% | ||
| Q2 24 | 178.2% | -89.5% | ||
| Q1 24 | 220.2% | -156.8% |
每股收益（稀释后）ALRARE
| Q4 25 | $1.49 | $-1.28 | ||
| Q3 25 | $1.21 | $-1.81 | ||
| Q2 25 | $3.33 | $-1.17 | ||
| Q1 25 | $3.26 | $-1.57 | ||
| Q4 24 | $0.83 | $-1.34 | ||
| Q3 24 | $0.82 | $-1.40 | ||
| Q2 24 | $0.81 | $-1.52 | ||
| Q1 24 | $0.87 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.4M | $421.0M |
| 总债务越低越好 | $19.7B | — |
| 股东权益账面价值 | $8.5B | $-80.0M |
| 总资产 | $32.9B | $1.5B |
| 负债/权益比越低杠杆越低 | 2.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALRARE
| Q4 25 | $466.4M | $421.0M | ||
| Q3 25 | $452.2M | $202.5M | ||
| Q2 25 | $454.8M | $176.3M | ||
| Q1 25 | $456.6M | $127.1M | ||
| Q4 24 | $472.6M | $174.0M | ||
| Q3 24 | $460.8M | $150.6M | ||
| Q2 24 | $454.1M | $480.7M | ||
| Q1 24 | $554.4M | $112.3M |
总债务ALRARE
| Q4 25 | $19.7B | — | ||
| Q3 25 | $20.2B | — | ||
| Q2 25 | $20.3B | — | ||
| Q1 25 | $19.9B | — | ||
| Q4 24 | $20.2B | — | ||
| Q3 24 | $20.2B | — | ||
| Q2 24 | $19.7B | — | ||
| Q1 24 | $19.5B | — |
股东权益ALRARE
| Q4 25 | $8.5B | $-80.0M | ||
| Q3 25 | $8.3B | $9.2M | ||
| Q2 25 | $8.2B | $151.3M | ||
| Q1 25 | $7.9B | $144.2M | ||
| Q4 24 | $7.5B | $255.0M | ||
| Q3 24 | $7.7B | $346.8M | ||
| Q2 24 | $7.3B | $432.4M | ||
| Q1 24 | $7.2B | $140.3M |
总资产ALRARE
| Q4 25 | $32.9B | $1.5B | ||
| Q3 25 | $33.4B | $1.2B | ||
| Q2 25 | $33.3B | $1.3B | ||
| Q1 25 | $32.4B | $1.3B | ||
| Q4 24 | $32.3B | $1.5B | ||
| Q3 24 | $32.2B | $1.5B | ||
| Q2 24 | $31.0B | $1.6B | ||
| Q1 24 | $30.9B | $1.3B |
负债/权益比ALRARE
| Q4 25 | 2.33× | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | 2.47× | — | ||
| Q1 25 | 2.53× | — | ||
| Q4 24 | 2.68× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 2.69× | — | ||
| Q1 24 | 2.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $414.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $342.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 242.9% | -48.6% |
| 资本支出强度资本支出/营收 | 51.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $-472.0M |
8季度趋势，按日历期对齐
经营现金流ALRARE
| Q4 25 | $414.1M | $-99.8M | ||
| Q3 25 | $458.6M | $-91.4M | ||
| Q2 25 | $473.6M | $-108.3M | ||
| Q1 25 | $388.3M | $-166.5M | ||
| Q4 24 | $430.0M | $-79.3M | ||
| Q3 24 | $461.9M | $-67.0M | ||
| Q2 24 | $413.8M | $-77.0M | ||
| Q1 24 | $371.3M | $-190.7M |
自由现金流ALRARE
| Q4 25 | $342.1M | $-100.8M | ||
| Q3 25 | $412.3M | $-92.7M | ||
| Q2 25 | $427.1M | $-110.7M | ||
| Q1 25 | $315.5M | $-167.8M | ||
| Q4 24 | $326.8M | $-79.5M | ||
| Q3 24 | $369.8M | $-68.6M | ||
| Q2 24 | $346.4M | $-79.0M | ||
| Q1 24 | $246.8M | $-193.9M |
自由现金流率ALRARE
| Q4 25 | 242.9% | -48.6% | ||
| Q3 25 | 926.6% | -58.0% | ||
| Q2 25 | 806.0% | -66.5% | ||
| Q1 25 | 339.5% | -120.5% | ||
| Q4 24 | 441.8% | -48.3% | ||
| Q3 24 | 569.1% | -49.2% | ||
| Q2 24 | 599.5% | -53.7% | ||
| Q1 24 | 503.8% | -178.2% |
资本支出强度ALRARE
| Q4 25 | 51.1% | 0.5% | ||
| Q3 25 | 104.1% | 0.8% | ||
| Q2 25 | 87.8% | 1.5% | ||
| Q1 25 | 78.4% | 1.0% | ||
| Q4 24 | 139.6% | 0.1% | ||
| Q3 24 | 141.7% | 1.2% | ||
| Q2 24 | 116.7% | 1.4% | ||
| Q1 24 | 254.3% | 3.0% |
现金转化率ALRARE
| Q4 25 | 2.29× | — | ||
| Q3 25 | 3.13× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 3.81× | — | ||
| Q3 24 | 4.44× | — | ||
| Q2 24 | 4.02× | — | ||
| Q1 24 | 3.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AL
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
